Late-life targeting of the IGF-1 receptor improves healthspan and lifespan in female mice

Academic Article


  • Diminished growth factor signaling improves longevity in laboratory models, while a reduction in the somatotropic axis is favorably linked to human aging and longevity. Given the conserved role of this pathway on lifespan, therapeutic strategies, such as insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibodies (mAb), represent a promising translational tool to target human aging. To this end, we performed a preclinical study in 18-mo-old male and female mice treated with vehicle or an IGF-1R mAb (L2-Cmu, Amgen Inc), and determined effects on aging outcomes. Here we show that L2-Cmu preferentially improves female healthspan and increases median lifespan by 9% (P = 0.03) in females, along with a reduction in neoplasms and inflammation (P ≤ 0.05). Thus, consistent with other models, targeting IGF-1R signaling appears to be most beneficial to females. Importantly, these effects could be achieved at advanced ages, suggesting that IGF-1R mAbs could represent a promising therapeutic candidate to delay aging.
  • Authors

    Published In

    Digital Object Identifier (doi)

    Author List

  • Mao K; Quipildor GF; Tabrizian T; Novaj A; Guan F; Walters RO; Delahaye F; Hubbard GB; Ikeno Y; Ejima K
  • Volume

  • 9
  • Issue

  • 1